When was Miltenyi Biotec founded?

Miltenyi Biotec was founded in 1989 and raised its 1st funding round 21 years after it was founded.

Where is Miltenyi Biotec located?

Miltenyi Biotec is headquartered in Bergisch Gladbach, Germany. It is registered at Auburn, California.

Who is the current CEO of Miltenyi Biotec?

Boris Stoffel of Miltenyi Biotec.

How many employees does Miltenyi Biotec have?

As of Jul 31, 2026, the latest employee count at Miltenyi Biotec is 3346.

Is Miltenyi Biotec a funded company?

Miltenyi Biotec is a funded company, having raised an undisclosed amount across 17 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jan 11, 2010.

When was the latest funding round of Miltenyi Biotec?

Miltenyi Biotec's latest funding was a $***** Grant (prize money) round on Mar 01, 2021, with participation from 1 investor. Its primary sector is Genomics. In Germany, the Genomics sector has seen $24.4M in funding in 2026 to date.

What is the annual revenue of Miltenyi Biotec?

Annual revenue of Miltenyi Biotec is between £500M and £1B as on Dec 31, 2024

Where does Miltenyi Biotec rank among its competitors?

Miltenyi Biotec ranks 33rd amongst 2925 active competitors, of which 511 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was LifeMine Therapeutics, which secured $75M in Aug, 2026.

Who are the top competitors of Miltenyi Biotec?

Miltenyi Biotec's top competitors include Abcam, Antheia and Transcenta. Among them, LifeMine Therapeutics secured the most recent funding round in August, 2026.

Miltenyi Biotec - 2026 Company Profile, Team, Funding, Competitors & Financials

Miltenyi Biotec is a funded company based in Bergisch Gladbach (Germany), founded in 1989 by Stefan Miltenyi. It operates as a Develops tools and products for research and clinical application. Miltenyi Biotec has raised an undisclosed amount in funding. The company has 2925 active competitors, including 511 funded and 443 that have exited. Its top competitors include companies like Abcam, Antheia and Transcenta.

Company Details

Develops tools and products for research and clinical application. The company offers biomedical research and cellular therapy products for cell isolation, flow cytometry, sample preparation, cell culture, molecular analysis, clinical application, and imaging. They have expertise in immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis.

Website: www.miltenyibiotec.com/
Social
Registered Address: Auburn, California

Key Metrics

Founded Year

1989

Location

Bergisch Gladbach, Germany

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Mar 01, 2021, $*****

Investors

Europa & 1 more

Ranked

33^rd among 2925 active competitors

Annual Revenue

£500M - £1B as on Dec 31, 2024

Employee Count

3,346 as on Jul 31, 2026

Investment & Acquisitions

lino Biotech & 2 more

Similar Companies

Antheia & 2956 more

View Miltenyi Biotec's full profile

Miltenyi Biotec is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MILTENYI BIOTEC, INC. CIN: 680277164 , United States, Active	Dec 26, 999	-	569 (As on Dec 31, 2020)	-
MILTENYI BIOTEC NORTH AMERICA INC. CIN: 824304020 , United States, Active	Dec 31, 1999	-	844 (As on Dec 31, 2024)	-
MILTENYI BIOTEC INDIA PRIVATE LIMITED CIN: U32509TS2023PTC179183 , India, Active	Nov 20, 2023	₹10 - ₹50 Cr (As on Mar 31, 2025)	10 (As on Feb 29, 2024)
Miltenyi BiotecBV & Co. KG CIN: HRA 34194 , Germany, Active	Jul 31, 2019	£500M - £1B (As on Dec 31, 2024)	-

Miltenyi Biotec has raised funding over 17 rounds. Its first funding round was on Jan 11, 2010. Its latest funding round was a Grant (prize money) round on Mar 01, 2021 for $*****. 1 investor participated in its latest round. Miltenyi Biotec has 2 institutional investors.

Here is the list of recent funding rounds of Miltenyi Biotec:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 01, 2021	3232331	Grant (prize money)	3260724	4001443	3605113	2386968
Jan 01, 2021	2842317	Grant (prize money)	4898366	8185531	6863385	Europa
Jan 01, 2020	8632343	Grant (prize money)	6757143	2723572	3785696	Europa

Access funding benchmarks and valuations. Sign up today!

View details of Miltenyi Biotec's funding rounds and investors

The founders of Miltenyi Biotec is Stefan Miltenyi. Boris Stoffel is the CEO of Miltenyi Biotec.

Here are the details of Miltenyi Biotec's key team members:

Stefan Miltenyi: Founder & MD of Miltenyi Biotec.
Boris Stoffel: CEO of Miltenyi Biotec.

View details of Miltenyi Biotec's Founder profiles and Board Members

Miltenyi Biotec's employee count trend

Miltenyi Biotec has 3,346 employees as of Jul 26. Here is Miltenyi Biotec's employee count trend over the years:

Employee count trend for Miltenyi Biotec

Uncover Miltenyi Biotec's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Miltenyi Biotec include Abcam, Antheia and Transcenta. Here is the list of Top 10 competitors of Miltenyi Biotec, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Abcam 1998, Cambridge (United Kingdom), Acquired	Developer of biological reagents for life science research	$78.8M	Juno Investment Partners, Martlet Capital ... & 2 others	76/100
2nd	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
3rd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
4th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Loayal Valley Capital, Sino Biopharmaceutical ... & 18 others	65/100
5th	Meridian Bioscience 1976, Ohio (United States), Acquired	Molecular diagnostic device and kits	-	JobsOhio, NIH	65/100
6th	Enzo 1976, Farmingdale (United States), Acquired	Life science products and services for research, drug discovery, and manufacturing	$7M	-	65/100
7th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 14 others	64/100
8th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
9th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	TA Associates, UBS & 1 others	63/100
10th	LifeMine Therapeutics 2016, Watertown (United States), Series E	Developer of novel drugs from fungi via genome mining and recombinant overexpression	$563M	Fidelity Investments, 6 Dimensions Capital ... & 17 others	63/100
33rd	Miltenyi Biotec 1989, Bergisch Gladbach (Germany), Funding Raised	Develops tools and products for research and clinical application	-	Europa, HHS	58/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Miltenyi Biotec's competitors? Click here to see the top ones

Miltenyi Biotec has acquired 3 companies including lino Biotech, LaVision BioTec and Lentigen. Miltenyi Biotec has not made any investments as of now.

Here is the list of its acquisitions:

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Feb 22, 2023	Acquisition	lino Biotech	2020	Zurich (Switzerland)
Oct 12, 2018	Acquisition	LaVision BioTec	2000	Bielefeld (Germany)
Aug 14, 2014	Acquisition	Lentigen	2004	Gaithersburg (United States)